Asset Details
Do you wish to reserve the book?
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Do you wish to request the book?
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
2014
Overview
Patients with hyperlipidemia were assigned to receive the PCSK9 antibody evolocumab or placebo on a background of lipid-lowering therapy. At 52 weeks, the least-squares mean reduction in LDL cholesterol from baseline for evolocumab versus placebo was 57%.
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that is produced predominantly in the liver, is secreted into the plasma and plays a major role in regulating levels of low-density lipoprotein (LDL) cholesterol by binding to hepatic LDL receptors and promoting their degradation.
1
,
2
In short-term (8-to-12-week), placebo-controlled, phase 2 trials, PCSK9 inhibitors have been shown to significantly reduce LDL cholesterol levels.
3
–
9
Four of these trials involved the use of evolocumab (AMG 145), a fully human monoclonal PCSK9 antibody, and assessed different doses and regimens in diverse patient populations with varying lipid phenotypes, cardiovascular disease risks, and baseline . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - therapeutic use
/ Azetidines - therapeutic use
/ Biological and medical sciences
/ Diet
/ Disorders of blood lipids. Hyperlipoproteinemia
/ Female
/ Heptanoic Acids - therapeutic use
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Hyperlipidemias - diet therapy
/ Hyperlipidemias - drug therapy
/ Kexin
/ Male
/ Pain
/ Patients
/ Proprotein Convertases - antagonists & inhibitors
/ Proprotein Convertases - immunology
